2zd1 › Citations

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.

Das K, Bauman JD, Clark AD, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E
Proc Natl Acad Sci U S A 105 1466-71 (2008)
Related entries: 1hpz, 1hqe, 1hqu, 1s6p, 1s6q, 1s9e, 1s9g, 1suq, 1sv5, 1tvr, 1uwb, 2iaj, 2ic3, 2ze2, 3bgr

Cited: 220 times
EuropePMC logo PMID: 18230722

Abstract

TMC278 is a diarylpyrimidine (DAPY) nonnucleoside reverse transcriptase inhibitor (NNRTI) that is highly effective in treating wild-type and drug-resistant HIV-1 infections in clinical trials at relatively low doses ( approximately 25-75 mg/day). We have determined the structure of wild-type HIV-1 RT complexed with TMC278 at 1.8 A resolution, using an RT crystal form engineered by systematic RT mutagenesis. This high-resolution structure reveals that the cyanovinyl group of TMC278 is positioned in a hydrophobic tunnel connecting the NNRTI-binding pocket to the nucleic acid-binding cleft. The crystal structures of TMC278 in complexes with the double mutant K103N/Y181C (2.1 A) and L100I/K103N HIV-1 RTs (2.9 A) demonstrated that TMC278 adapts to bind mutant RTs. In the K103N/Y181C RT/TMC278 structure, loss of the aromatic ring interaction caused by the Y181C mutation is counterbalanced by interactions between the cyanovinyl group of TMC278 and the aromatic side chain of Y183, which is facilitated by an approximately 1.5 A shift of the conserved Y(183)MDD motif. In the L100I/K103N RT/TMC278 structure, the binding mode of TMC278 is significantly altered so that the drug conforms to changes in the binding pocket primarily caused by the L100I mutation. The flexible binding pocket acts as a molecular "shrink wrap" that makes a shape complementary to the optimized TMC278 in wild-type and drug-resistant forms of HIV-1 RT. The crystal structures provide a better understanding of how the flexibility of an inhibitor can compensate for drug-resistance mutations.

Reviews - 2zd1 mentioned but not cited (7)

  1. The structural biology of HIV-1: mechanistic and therapeutic insights. Engelman A, Cherepanov P. Nat Rev Microbiol 10 279-290 (2012)
  2. Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. Singh K, Flores JA, Kirby KA, Neogi U, Sonnerborg A, Hachiya A, Das K, Arnold E, McArthur C, Parniak M, Sarafianos SG. Viruses 6 3535-3562 (2014)
  3. Avoiding Drug Resistance in HIV Reverse Transcriptase. Cilento ME, Kirby KA, Sarafianos SG. Chem Rev 121 3271-3296 (2021)
  4. Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review. Tarasova O, Poroikov V, Veselovsky A. Molecules 23 E1233 (2018)
  5. Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Zhuang C, Pannecouque C, De Clercq E, Chen F. Acta Pharm Sin B 10 961-978 (2020)
  6. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors. Santos LH, Ferreira RS, Caffarena ER. Mem Inst Oswaldo Cruz 110 847-864 (2015)
  7. Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies. Singh AK, Das K. Viruses 14 1027 (2022)

Articles - 2zd1 mentioned but not cited (53)

  1. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Das K, Bauman JD, Clark AD, Frenkel YV, Lewi PJ, Shatkin AJ, Hughes SH, Arnold E. Proc Natl Acad Sci U S A 105 1466-1471 (2008)
  2. Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E, Le Grice SF. J Med Chem 54 4462-4473 (2011)
  3. Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations. Ivetac A, McCammon JA. J Mol Biol 388 644-658 (2009)
  4. Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase. Kuroda DG, Bauman JD, Challa JR, Patel D, Troxler T, Das K, Arnold E, Hochstrasser RM. Nat Chem 5 174-181 (2013)
  5. Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG. Viruses 2 606-638 (2010)
  6. Biochemical mechanism of HIV-1 resistance to rilpivirine. Singh K, Marchand B, Rai DK, Sharma B, Michailidis E, Ryan EM, Matzek KB, Leslie MD, Hagedorn AN, Li Z, Norden PR, Hachiya A, Parniak MA, Xu HT, Wainberg MA, Sarafianos SG. J Biol Chem 287 38110-38123 (2012)
  7. Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. Frey KM, Bollini M, Mislak AC, Cisneros JA, Gallardo-Macias R, Jorgensen WL, Anderson KS. J Am Chem Soc 134 19501-19503 (2012)
  8. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. Namasivayam V, Vanangamudi M, Kramer VG, Kurup S, Zhan P, Liu X, Kongsted J, Byrareddy SN. J Med Chem 62 4851-4883 (2019)
  9. Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development. van Westen GJ, Wegner JK, Geluykens P, Kwanten L, Vereycken I, Peeters A, Ijzerman AP, van Vlijmen HW, Bender A. PLoS One 6 e27518 (2011)
  10. Ribonuclease H/DNA Polymerase HIV-1 Reverse Transcriptase Dual Inhibitor: Mechanistic Studies on the Allosteric Mode of Action of Isatin-Based Compound RMNC6. Corona A, Meleddu R, Esposito F, Distinto S, Bianco G, Masaoka T, Maccioni E, Menéndez-Arias L, Alcaro S, Le Grice SF, Tramontano E. PLoS One 11 e0147225 (2016)
  11. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. Qin B, Jiang X, Lu H, Tian X, Barbault F, Huang L, Qian K, Chen CH, Huang R, Jiang S, Lee KH, Xie L. J Med Chem 53 4906-4916 (2010)
  12. Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase. Meleddu R, Distinto S, Corona A, Tramontano E, Bianco G, Melis C, Cottiglia F, Maccioni E. J Enzyme Inhib Med Chem 32 130-136 (2017)
  13. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants. Johnson BC, Pauly GT, Rai G, Patel D, Bauman JD, Baker HL, Das K, Schneider JP, Maloney DJ, Arnold E, Thomas CJ, Hughes SH. Retrovirology 9 99 (2012)
  14. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures. Paris KA, Haq O, Felts AK, Das K, Arnold E, Levy RM. J Med Chem 52 6413-6420 (2009)
  15. Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility. Bollini M, Frey KM, Cisneros JA, Spasov KA, Das K, Bauman JD, Arnold E, Anderson KS, Jorgensen WL. Bioorg Med Chem Lett 23 5209-5212 (2013)
  16. Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs. Himmel DM, Myshakina NS, Ilina T, Van Ry A, Ho WC, Parniak MA, Arnold E. J Mol Biol 426 2617-2631 (2014)
  17. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Tian X, Qin B, Wu Z, Wang X, Lu H, Morris-Natschke SL, Chen CH, Jiang S, Lee KH, Xie L. J Med Chem 53 8287-8297 (2010)
  18. Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets. Allen WJ, Fochtman BC, Balius TE, Rizzo RC. J Comput Chem 38 2641-2663 (2017)
  19. Letter Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual screening of experimental and theoretical ensembles. Ivetac A, Swift SE, Boyer PL, Diaz A, Naughton J, Young JA, Hughes SH, McCammon JA. Chem Biol Drug Des 83 521-531 (2014)
  20. Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase. Frey KM, Gray WT, Spasov KA, Bollini M, Gallardo-Macias R, Jorgensen WL, Anderson KS. Chem Biol Drug Des 83 541-549 (2014)
  21. Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance. Gray WT, Frey KM, Laskey SB, Mislak AC, Spasov KA, Lee WG, Bollini M, Siliciano RF, Jorgensen WL, Anderson KS. ACS Med Chem Lett 6 1075-1079 (2015)
  22. The interplay of structure and dynamics: insights from a survey of HIV-1 reverse transcriptase crystal structures. Seckler JM, Leioatts N, Miao H, Grossfield A. Proteins 81 1792-1801 (2013)
  23. Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy. Bailey CM, Sullivan TJ, Iyidogan P, Tirado-Rives J, Chung R, Ruiz-Caro J, Mohamed E, Jorgensen WL, Hunter R, Anderson KS. J Med Chem 56 3959-3968 (2013)
  24. Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus. van Hemert FJ, Berkhout B, Zaaijer HL. PLoS One 9 e106324 (2014)
  25. Mining protein dynamics from sets of crystal structures using "consensus structures". van Westen GJ, Wegner JK, Bender A, Ijzerman AP, van Vlijmen HW. Protein Sci 19 742-752 (2010)
  26. Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase. Cullen MD, Ho WC, Bauman JD, Das K, Arnold E, Hartman TL, Watson KM, Buckheit RW, Pannecouque C, De Clercq E, Cushman M. J Med Chem 52 6467-6473 (2009)
  27. From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors. Massari S, Corona A, Distinto S, Desantis J, Caredda A, Sabatini S, Manfroni G, Felicetti T, Cecchetti V, Pannecouque C, Maccioni E, Tramontano E, Tabarrini O. J Enzyme Inhib Med Chem 34 55-74 (2019)
  28. A Sister Lineage of Sampled Retroviruses Corroborates the Complex Evolution of Retroviruses. Wang J, Han GZ. Mol Biol Evol 38 1031-1039 (2021)
  29. Local conformational changes in the DNA interfaces of proteins. Sunami T, Kono H. PLoS One 8 e56080 (2013)
  30. Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. Smith SJ, Pauly GT, Akram A, Melody K, Rai G, Maloney DJ, Ambrose Z, Thomas CJ, Schneider JT, Hughes SH. Retrovirology 13 11 (2016)
  31. Role of Ligand Reorganization and Conformational Restraints on the Binding Free Energies of DAPY Non-Nucleoside Inhibitors to HIV Reverse Transcriptase. Gallicchio E. Comput Mol Biosci 2 7-22 (2012)
  32. Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. Putz MV, Dudaș NA, Isvoran A. Int J Mol Sci 16 19553-19601 (2015)
  33. Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. Neogi U, Häggblom A, Singh K, Rogers LC, Rao SD, Amogne W, Schülter E, Zazzi M, Arnold E, Sarafianos SG, Sönnerborg A. J Antimicrob Chemother 71 367-371 (2016)
  34. Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Jin K, Liu M, Zhuang C, De Clercq E, Pannecouque C, Meng G, Chen F. Acta Pharm Sin B 10 344-357 (2020)
  35. A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase. Mislak AC, Frey KM, Bollini M, Jorgensen WL, Anderson KS. Biochim Biophys Acta 1840 2203-2211 (2014)
  36. An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors. Pagano N, Teriete P, Mattmann ME, Yang L, Snyder BA, Cai Z, Heil ML, Cosford NDP. Bioorg Med Chem 25 6248-6265 (2017)
  37. What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors? Paneth A, Płonka W, Paneth P. J Mol Model 23 317 (2017)
  38. An RNAi in silico approach to find an optimal shRNA cocktail against HIV-1. Méndez-Ortega MC, Restrepo S, Rodríguez-R LM, Pérez I, Mendoza JC, Martínez AP, Sierra R, Rey-Benito GJ. Virol J 7 369 (2010)
  39. Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants. Smith SJ, Pauly GT, Hewlett K, Schneider JP, Hughes SH. Chem Biol Drug Des 97 4-17 (2021)
  40. Systematic Identification of Machine-Learning Models Aimed to Classify Critical Residues for Protein Function from Protein Structure. Corral-Corral R, Beltrán JA, Brizuela CA, Del Rio G. Molecules 22 E1673 (2017)
  41. Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring. Paneth A, Płonka W, Paneth P. Pharmaceuticals (Basel) 12 64 (2019)
  42. Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition. Bernardo CE, Silva PJ. PeerJ 2 e470 (2014)
  43. NMR structure of the HIV-1 reverse transcriptase thumb subdomain. Sharaf NG, Brereton AE, Byeon IL, Karplus PA, Gronenborn AM. J Biomol NMR 66 273-280 (2016)
  44. Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy. Lei Y, Han S, Yang Y, Pannecouque C, De Clercq E, Zhuang C, Chen FE. Molecules 25 E1050 (2020)
  45. Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase. Iyidogan P, Sullivan TJ, Chordia MD, Frey KM, Anderson KS. ACS Med Chem Lett 4 1183-1188 (2013)
  46. Exploring New Scaffolds for the Dual Inhibition of HIV-1 RT Polymerase and Ribonuclease Associated Functions. Meleddu R, Corona A, Distinto S, Cottiglia F, Deplano S, Sequeira L, Secci D, Onali A, Sanna E, Esposito F, Cirone I, Ortuso F, Alcaro S, Tramontano E, Mátyus P, Maccioni E. Molecules 26 3821 (2021)
  47. Novel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy. Chaillon A, Gianella S, Vazquez H, Ignacio C, Zweig AC, Richman DD, Smith DM. AIDS Res Hum Retroviruses 30 165-169 (2014)
  48. Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs. Li TT, Pannecouque C, De Clercq E, Zhuang CL, Chen FE. Molecules 25 E1581 (2020)
  49. 5-Nitro-3-(2-(4-phenylthiazol-2-yl)hydrazineylidene)indolin-2-one derivatives inhibit HIV-1 replication by a multitarget mechanism of action. Corona A, Meleddu R, Delelis O, Subra F, Cottiglia F, Esposito F, Distinto S, Maccioni E, Tramontano E. Front Cell Infect Microbiol 13 1193280 (2023)
  50. Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines. Gasparyan SP, Martirosyan AH, Alexanyan MV, Harutyunyan GK, Chilingaryan GV, Coats S, Schinazi RF. Mol Divers 25 2045-2052 (2021)
  51. Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability. Jin X, Wang S, Zhao L, Huang W, Zhang Y, Pannecouque C, De Clercq E, Meng G, Piao H, Chen F. Acta Pharm Sin B 13 1192-1203 (2023)
  52. Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region. Zhang T, Zhou Z, Zhao F, Sang Z, De Clercq E, Pannecouque C, Kang D, Zhan P, Liu X. Pharmaceuticals (Basel) 15 1438 (2022)
  53. Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability. Sang YL, Pannecouque C, De Clercq E, Wang S, Chen FE. Acta Pharm Sin B 13 3054-3066 (2023)


Reviews citing this publication (38)

  1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). de Béthune MP. Antiviral Res 85 75-90 (2010)
  2. Structure and dynamics of a processive Brownian motor: the translating ribosome. Frank J, Gonzalez RL. Annu Rev Biochem 79 381-412 (2010)
  3. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Menéndez-Arias L. Antiviral Res 98 93-120 (2013)
  4. Molecular basis of human immunodeficiency virus drug resistance: an update. Menéndez-Arias L. Antiviral Res 85 210-231 (2010)
  5. Current perspectives on HIV-1 antiretroviral drug resistance. Iyidogan P, Anderson KS. Viruses 6 4095-4139 (2014)
  6. Novel approaches to inhibiting HIV-1 replication. Adamson CS, Freed EO. Antiviral Res 85 119-141 (2010)
  7. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Das K, Arnold E. Curr Opin Virol 3 111-118 (2013)
  8. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Zhan P, Chen X, Li D, Fang Z, De Clercq E, Liu X. Med Res Rev 33 Suppl 1 E1-72 (2013)
  9. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Das K, Arnold E. Curr Opin Virol 3 119-128 (2013)
  10. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Ann Pharmacother 44 157-165 (2010)
  11. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. De Clercq E. Med Res Rev 29 611-645 (2009)
  12. In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Reynolds C, de Koning CB, Pelly SC, van Otterlo WA, Bode ML. Chem Soc Rev 41 4657-4670 (2012)
  13. The search for potent, small molecule NNRTIs: A review. Prajapati DG, Ramajayam R, Yadav MR, Giridhar R. Bioorg Med Chem 17 5744-5762 (2009)
  14. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. De Clercq E. Biochem Pharmacol 84 241-248 (2012)
  15. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Fulco PP, McNicholl IR. Pharmacotherapy 29 281-294 (2009)
  16. Reverse Transcription of Retroviruses and LTR Retrotransposons. Hughes SH. Microbiol Spectr 3 MDNA3-0027-2014 (2015)
  17. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. Spratt AN, Gallazzi F, Quinn TP, Lorson CL, Sönnerborg A, Singh K. Expert Opin Ther Pat 31 339-350 (2021)
  18. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. Croxtall JD. Drugs 72 847-869 (2012)
  19. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Ripamonti D, Bombana E, Rizzi M. Expert Rev Anti Infect Ther 12 13-29 (2014)
  20. Dancing with chemical formulae of antivirals: a personal account. De Clercq E. Biochem Pharmacol 86 711-725 (2013)
  21. Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance. Xavier Ruiz F, Arnold E. Curr Opin Struct Biol 61 113-123 (2020)
  22. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors. La Regina G, Coluccia A, Silvestri R. Antivir Chem Chemother 20 213-237 (2010)
  23. A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Agnello S, Brand M, Chellat MF, Gazzola S, Riedl R. Angew Chem Int Ed Engl 58 3300-3345 (2019)
  24. Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions. De Clercq E. Med Res Rev 30 667-707 (2010)
  25. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Huang B, Kang D, Yang J, Zhan P, Liu X. Expert Opin Ther Pat 26 281-289 (2016)
  26. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Zaharatos GJ, Wainberg MA. Ann Med 45 236-241 (2013)
  27. The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Wainberg MA. Scientifica (Cairo) 2012 238278 (2012)
  28. Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV. Himmel DM, Arnold E. Pharmaceuticals (Basel) 13 E122 (2020)
  29. Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants. Frey KM. Future Microbiol 10 1767-1772 (2015)
  30. An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients. Putcharoen O, Kerr SJ, Ruxrungtham K. HIV AIDS (Auckl) 5 231-241 (2013)
  31. Ligands and Receptors with Broad Binding Capabilities Have Common Structural Characteristics: An Antibiotic Design Perspective. Abrusán G, Marsh JA. J Med Chem 62 9357-9374 (2019)
  32. Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. Hol WG. Acta Crystallogr F Struct Biol Commun 71 485-499 (2015)
  33. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis. Li SL, Xu P, Zhang L, Sun GX, Lu ZJ. HIV Clin Trials 15 261-268 (2014)
  34. The "Sticky Patch" Model of Crystallization and Modification of Proteins for Enhanced Crystallizability. Derewenda ZS, Godzik A. Methods Mol Biol 1607 77-115 (2017)
  35. [Resistance profile of rilpivirine]. Imaz A, García F, di Yacovo S, Llibre JM. Enferm Infecc Microbiol Clin 31 Suppl 2 36-43 (2013)
  36. Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology. Pereira M, Vale N. Int J Mol Sci 24 2890 (2023)
  37. Large Multidomain Protein NMR: HIV-1 Reverse Transcriptase Precursor in Solution. Ilina TV, Xi Z, Brosenitsch T, Sluis-Cremer N, Ishima R. Int J Mol Sci 21 E9545 (2020)
  38. [Mechanism of action and pharmacokinetics of rilpivirine]. Portilla J, Estrada V. Enferm Infecc Microbiol Clin 31 Suppl 2 2-5 (2013)

Articles citing this publication (122)

  1. DOCK 6: Impact of new features and current docking performance. Allen WJ, Balius TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, Case DA, Kuntz ID, Rizzo RC. J Comput Chem 36 1132-1156 (2015)
  2. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. Antimicrob Agents Chemother 54 718-727 (2010)
  3. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. Mol Pharmacol 80 565-572 (2011)
  4. Applications of 2D IR spectroscopy to peptides, proteins, and hydrogen-bond dynamics. Kim YS, Hochstrasser RM. J Phys Chem B 113 8231-8251 (2009)
  5. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, de Bethune MP, Nuttall J, Romano J, Shattock R. Antimicrob Agents Chemother 53 487-495 (2009)
  6. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K, TMC278-C204 Study Group. AIDS 24 55-65 (2010)
  7. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. Bollini M, Domaoal RA, Thakur VV, Gallardo-Macias R, Spasov KA, Anderson KS, Jorgensen WL. J Med Chem 54 8582-8591 (2011)
  8. Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase. Fang C, Bauman JD, Das K, Remorino A, Arnold E, Hochstrasser RM. Proc Natl Acad Sci U S A 105 1472-1477 (2008)
  9. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Bauman JD, Das K, Ho WC, Baweja M, Himmel DM, Clark AD, Oren DA, Boyer PL, Hughes SH, Shatkin AJ, Arnold E. Nucleic Acids Res 36 5083-5092 (2008)
  10. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR. Chem Biol 17 46-56 (2010)
  11. Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B. Powdrill MH, Bernatchez JA, Götte M. Viruses 2 2169-2195 (2010)
  12. Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. Antimicrob Agents Chemother 56 5000-5008 (2012)
  13. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Wilson DP, Coplan PM, Wainberg MA, Blower SM. Proc Natl Acad Sci U S A 105 9835-9840 (2008)
  14. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA. Antimicrob Agents Chemother 57 3100-3109 (2013)
  15. Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. Zeevaart JG, Wang L, Thakur VV, Leung CS, Tirado-Rives J, Bailey CM, Domaoal RA, Anderson KS, Jorgensen WL. J Am Chem Soc 130 9492-9499 (2008)
  16. Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. Jorgensen WL, Bollini M, Thakur VV, Domaoal RA, Spasov KA, Anderson KS. J Am Chem Soc 133 15686-15696 (2011)
  17. Large scale affinity calculations of cyclodextrin host-guest complexes: Understanding the role of reorganization in the molecular recognition process. Wickstrom L, He P, Gallicchio E, Levy RM. J Chem Theory Comput 9 3136-3150 (2013)
  18. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. Das K, Bauman JD, Rim AS, Dharia C, Clark AD, Camarasa MJ, Balzarini J, Arnold E. J Med Chem 54 2727-2737 (2011)
  19. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, Wainberg MA. Antimicrob Agents Chemother 56 751-756 (2012)
  20. Structural modifications of DAPY analogues with potent anti-HIV-1 activity. Feng XQ, Liang YH, Zeng ZS, Chen FE, Balzarini J, Pannecouque C, De Clercq E. ChemMedChem 4 219-224 (2009)
  21. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. Smith SJ, Pauly GT, Akram A, Melody K, Ambrose Z, Schneider JP, Hughes SH. J Acquir Immune Defic Syndr 72 485-491 (2016)
  22. 2D IR photon echo spectroscopy reveals hydrogen bond dynamics of aromatic nitriles. Ghosh A, Remorino A, Tucker MJ, Hochstrasser RM. Chem Phys Lett 469 325-330 (2009)
  23. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. AIDS 27 879-887 (2013)
  24. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors. Zhao XZ, Smith SJ, Maskell DP, Métifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR. J Med Chem 60 7315-7332 (2017)
  25. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. Frey KM, Puleo DE, Spasov KA, Bollini M, Jorgensen WL, Anderson KS. J Med Chem 58 2737-2745 (2015)
  26. Design, synthesis, and biological evaluation of 1,3-diarylpropenones as dual inhibitors of HIV-1 reverse transcriptase. Meleddu R, Cannas V, Distinto S, Sarais G, Del Vecchio C, Esposito F, Bianco G, Corona A, Cottiglia F, Alcaro S, Parolin C, Artese A, Scalise D, Fresta M, Arridu A, Ortuso F, Maccioni E, Tramontano E. ChemMedChem 9 1869-1879 (2014)
  27. Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. Chung S, Miller JT, Johnson BC, Hughes SH, Le Grice SF. J Biol Chem 287 4066-4075 (2012)
  28. Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase. Boyer PL, Smith SJ, Zhao XZ, Das K, Gruber K, Arnold E, Burke TR, Hughes SH. J Virol 92 e02203-17 (2018)
  29. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. Sweeney ZK, Dunn JP, Li Y, Heilek G, Dunten P, Elworthy TR, Han X, Harris SF, Hirschfeld DR, Hogg JH, Huber W, Kaiser AC, Kertesz DJ, Kim W, Mirzadegan T, Roepel MG, Saito YD, Silva TM, Swallow S, Tracy JL, Villasenor A, Vora H, Zhou AS, Klumpp K. Bioorg Med Chem Lett 18 4352-4354 (2008)
  30. Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. Dunn LL, McWilliams MJ, Das K, Arnold E, Hughes SH. J Virol 83 12336-12344 (2009)
  31. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks. Mills AM, Antinori A, Clotet B, Fourie J, Herrera G, Hicks C, Madruga JV, Vanveggel S, Stevens M, Boven K, ECHO and THRIVE study groups. HIV Med 14 391-400 (2013)
  32. Conformational Plasticity of the NNRTI-Binding Pocket in HIV-1 Reverse Transcriptase: A Fluorine Nuclear Magnetic Resonance Study. Sharaf NG, Ishima R, Gronenborn AM. Biochemistry 55 3864-3873 (2016)
  33. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. Chan AH, Lee WG, Spasov KA, Cisneros JA, Kudalkar SN, Petrova ZO, Buckingham AB, Anderson KS, Jorgensen WL. Proc Natl Acad Sci U S A 114 9725-9730 (2017)
  34. HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate. Maga G, Radi M, Gerard MA, Botta M, Ennifar E. Viruses 2 880-899 (2010)
  35. Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors. Ma XD, Yang SQ, Gu SX, He QQ, Chen FE, De Clercq E, Balzarini J, Pannecouque C. ChemMedChem 6 2225-2232 (2011)
  36. Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. Li X, Chen W, Tian Y, Liu H, Zhan P, De Clercq E, Pannecouque C, Balzarini J, Liu X. Eur J Med Chem 80 112-121 (2014)
  37. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. Yang Y, Kang D, Nguyen LA, Smithline ZB, Pannecouque C, Zhan P, Liu X, Steitz TA. Elife 7 e36340 (2018)
  38. A Comparative Study on the Constitutive Properties of Marketed Pesticides. Hao G, Dong Q, Yang G. Mol Inform 30 614-622 (2011)
  39. "Reverse" carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors. Zimmermann SC, Sadler JM, O'Daniel PI, Kim NT, Seley-Radtke KL. Nucleosides Nucleotides Nucleic Acids 32 137-154 (2013)
  40. In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation. Bustanji Y, Al-Masri IM, Qasem A, Al-Bakri AG, Taha MO. Chem Biol Drug Des 74 258-265 (2009)
  41. Synthetic Routes to a Series of Proximal and Distal 2'-Deoxy Fleximers. Wauchope OR, Velasquez M, Seley-Radtke K. Synthesis (Stuttg) 44 3496-3504 (2012)
  42. Design, synthesis, and biological evaluation of novel trifluoromethyl indoles as potent HIV-1 NNRTIs with an improved drug resistance profile. Jiang HX, Zhuang DM, Huang Y, Cao XX, Yao JH, Li JY, Wang JY, Zhang C, Jiang B. Org Biomol Chem 12 3446-3458 (2014)
  43. Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Tian X, Qin B, Lu H, Lai W, Jiang S, Lee KH, Chen CH, Xie L. Bioorg Med Chem Lett 19 5482-5485 (2009)
  44. It's all in the crystals…. Derewenda ZS. Acta Crystallogr D Biol Crystallogr 67 243-248 (2011)
  45. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity. Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA. J Virol 88 1536-1547 (2014)
  46. Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. Wainberg MA. HIV AIDS (Auckl) 5 41-49 (2013)
  47. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V. ChemMedChem 6 2203-2213 (2011)
  48. Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis. Betancor G, Álvarez M, Marcelli B, Andrés C, Martínez MA, Menéndez-Arias L. Nucleic Acids Res 43 2259-2270 (2015)
  49. Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity. Gatanaga H, Murakoshi H, Hachiya A, Hayashida T, Chikata T, Ode H, Tsuchiya K, Sugiura W, Takiguchi M, Oka S. Clin Infect Dis 57 1051-1055 (2013)
  50. Conformational populations of ligand-sized molecules by replica exchange molecular dynamics and temperature reweighting. Okumura H, Gallicchio E, Levy RM. J Comput Chem 31 1357-1367 (2010)
  51. Identification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex. Grigorov B, Bocquin A, Gabus C, Avilov S, Mély Y, Agopian A, Divita G, Gottikh M, Witvrouw M, Darlix JL. Nucleic Acids Res 39 5586-5596 (2011)
  52. Molecular insight on the binding of NNRTI to K103N mutated HIV-1 RT: molecular dynamics simulations and dynamic pharmacophore analysis. Nizami B, Sydow D, Wolber G, Honarparvar B. Mol Biosyst 12 3385-3395 (2016)
  53. Structural Basis of HIV-1 Inhibition by Nucleotide-Competing Reverse Transcriptase Inhibitor INDOPY-1. Ruiz FX, Hoang A, Das K, Arnold E. J Med Chem 62 9996-10002 (2019)
  54. Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Kudalkar SN, Beloor J, Chan AH, Lee WG, Jorgensen WL, Kumar P, Anderson KS. Mol Pharmacol 91 383-391 (2017)
  55. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors. Meng G, Liu Y, Zheng A, Chen F, Chen W, De Clercq E, Pannecouque C, Balzarini J. Eur J Med Chem 82 600-611 (2014)
  56. Direct detection of structurally resolved dynamics in a multiconformation receptor-ligand complex. Carroll MJ, Gromova AV, Miller KR, Tang H, Wang XS, Tripathy A, Singleton SF, Collins EJ, Lee AL. J Am Chem Soc 133 6422-6428 (2011)
  57. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Chen X, Li Y, Ding S, Balzarini J, Pannecouque C, De Clercq E, Liu H, Liu X. ChemMedChem 8 1117-1126 (2013)
  58. Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Murugesan V, Tiwari VS, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Makwana N, Suryawanshi R, Katti SB. Bioorg Med Chem 19 6919-6926 (2011)
  59. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. Murugesan V, Makwana N, Suryawanshi R, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Katti SB. Bioorg Med Chem 22 3159-3170 (2014)
  60. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S, Capparelli EV, Mirochnick M, IMPAACT P1026s Protocol Team. J Acquir Immune Defic Syndr 78 308-313 (2018)
  61. Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine. Sariyer IK, Gordon J, Burdo TH, Wollebo HS, Gianti E, Donadoni M, Bellizzi A, Cicalese S, Loomis R, Robinson JA, Carnevale V, Steiner J, Ozdener MH, Miller AD, Amini S, Klein ML, Khalili K. Mol Ther 27 2067-2079 (2019)
  62. 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. Kang D, Ruiz FX, Sun Y, Feng D, Jing L, Wang Z, Zhang T, Gao S, Sun L, De Clercq E, Pannecouque C, Arnold E, Zhan P, Liu X. J Med Chem 64 4239-4256 (2021)
  63. In silico Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines. Chen Y, Tian Y, Gao Y, Wu F, Luo X, Ju X, Liu G. Front Chem 8 164 (2020)
  64. Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity. Zimmermann SC, Sadler JM, Andrei G, Snoeck R, Balzarini J, Seley-Radtke KL. Medchemcomm 2 (2011)
  65. Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. Zhang H, Tian Y, Kang D, Huo Z, Zhou Z, Liu H, De Clercq E, Pannecouque C, Zhan P, Liu X. Eur J Med Chem 130 209-222 (2017)
  66. Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability. Frenkel YV, Gallicchio E, Das K, Levy RM, Arnold E. J Med Chem 52 5896-5905 (2009)
  67. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Fernández-Montero JV, Vispo E, Anta L, de Mendoza C, Soriano V. Expert Opin Pharmacother 13 1007-1014 (2012)
  68. Design, Synthesis, and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket. Chen X, Meng Q, Qiu L, Zhan P, Liu H, De Clercq E, Pannecouque C, Liu X. Chem Biol Drug Des 86 122-128 (2015)
  69. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. Kang D, Wang Z, Chen M, Feng D, Wu G, Zhou Z, Jing L, Zuo X, Jiang X, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X. Chem Biol Drug Des 93 430-437 (2019)
  70. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. Yang S, Pannecouque C, Daelemans D, Ma XD, Liu Y, Chen FE, De Clercq E. Eur J Med Chem 65 134-143 (2013)
  71. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors. Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, Petropoulos CJ, Wainberg MA. Antimicrob Agents Chemother 57 5649-5657 (2013)
  72. Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Kudalkar SN, Ullah I, Bertoletti N, Mandl HK, Cisneros JA, Beloor J, Chan AH, Quijano E, Saltzman WM, Jorgensen WL, Kumar P, Anderson KS. Antiviral Res 167 110-116 (2019)
  73. 1-Benzyl derivatives of 5-(arylamino)uracils as anti-HIV-1 and anti-EBV agents. Novikov MS, Buckheit RW, Temburnikar K, Khandazhinskaya AL, Ivanov AV, Seley-Radtke KL. Bioorg Med Chem 18 8310-8314 (2010)
  74. Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H. Xi Z, Wang Z, Sarafianos SG, Myshakina NS, Ishima R. ACS Infect Dis 5 1963-1974 (2019)
  75. Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics. Debnath U, Verma S, Jain S, Katti SB, Prabhakar YS. J Comput Aided Mol Des 27 637-654 (2013)
  76. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site. Sharaf NG, Xi Z, Ishima R, Gronenborn AM. Proteins 85 2191-2197 (2017)
  77. Design, synthesis, and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs. Tian Y, Rai D, Zhan P, Pannecouque C, Balzarini J, De Clercq E, Liu H, Liu X. Chem Biol Drug Des 82 384-393 (2013)
  78. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel". Zhou Z, Liu T, Kang D, Huo Z, Wu G, Daelemans D, De Clercq E, Pannecouque C, Zhan P, Liu X. Org Biomol Chem 16 1014-1028 (2018)
  79. Fast and automated functional classification with MED-SuMo: an application on purine-binding proteins. Doppelt-Azeroual O, Delfaud F, Moriaud F, de Brevern AG. Protein Sci 19 847-867 (2010)
  80. Impact of rtI233V mutation in hepatitis B virus polymerase protein and adefovir efficacy: Homology modeling and molecular docking studies. Ismail AM, Sharma OP, Kumar MS, Kannangai R, Abraham P. Bioinformation 9 121-125 (2013)
  81. Molecular mechanisms and design principles for promiscuous inhibitors to avoid drug resistance: lessons learned from HIV-1 protease inhibition. Shen Y, Radhakrishnan ML, Tidor B. Proteins 83 351-372 (2015)
  82. Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. Wu ZY, Liu N, Qin B, Huang L, Yu F, Qian K, Morris-Natschke SL, Jiang S, Chen CH, Lee KH, Xie L. ChemMedChem 9 1546-1555 (2014)
  83. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase. Zhang H, Qin F, Ye W, Li Z, Ma S, Xia Y, Jiang Y, Zhu J, Li Y, Zhang J, Chen HF. Chem Biol Drug Des 78 427-437 (2011)
  84. Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives. Chander S, Tang CR, Al-Maqtari HM, Jamalis J, Penta A, Hadda TB, Sirat HM, Zheng YT, Sankaranarayanan M. Bioorg Chem 72 74-79 (2017)
  85. Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. Kang D, Ruiz FX, Feng D, Pilch A, Zhao T, Wei F, Wang Z, Sun Y, Fang Z, De Clercq E, Pannecouque C, Arnold E, Liu X, Zhan P. J Med Chem 63 1298-1312 (2020)
  86. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Liu G, Wan Y, Wang W, Fang S, Gu S, Ju X. Mol Divers 23 107-121 (2019)
  87. Comment Drug-protein interactions: Mechanisms of potency. Cheatum CM. Nat Chem 5 152-153 (2013)
  88. Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France. Jeulin H, Foissac M, Boyer L, Agrinier N, Perrier P, Kennel A, Velay A, Goehringer F, Henard S, Rabaud C, May T, Schvoerer E. J Antimicrob Chemother 69 3095-3102 (2014)
  89. Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors. Liu Y, Meng G, Zheng A, Chen F, Chen W, De Clercq E, Pannecouque C, Balzarini J. Eur J Pharm Sci 62 334-341 (2014)
  90. Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root. Xu C, Xin Y, Chen M, Ba M, Guo Q, Zhu C, Guo Y, Shi J. Eur J Med Chem 189 112071 (2020)
  91. Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR. Li Z, Zhang H, Li Y, Zhang J, Chen HF. Chem Biol Drug Des 77 63-74 (2011)
  92. Inhibition activities of catechol diether based non-nucleoside inhibitors against the HIV reverse transcriptase variants: Insights from molecular docking and ONIOM calculations. Samanta PN, Das KK. J Mol Graph Model 75 294-305 (2017)
  93. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M. AIDS Res Hum Retroviruses 34 667-671 (2018)
  94. Protein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP. Zheng X, Mueller GA, DeRose EF, London RE. Biophys J 104 2695-2705 (2013)
  95. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations. Hayashida T, Hachiya A, Ode H, Nishijima T, Tsuchiya K, Sugiura W, Takiguchi M, Oka S, Gatanaga H. J Antimicrob Chemother 71 2760-2766 (2016)
  96. Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Schauer G, Leuba S, Sluis-Cremer N. Biomolecules 3 889-904 (2013)
  97. Investigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations. Monroe JI, El-Nahal WG, Shirts MR. Proteins 82 130-144 (2014)
  98. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. Patel N, Miller CD. HIV AIDS (Auckl) 4 61-71 (2012)
  99. Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). Huang B, Zhou Z, Kang D, Li W, Chen Z, Zhan P, Liu X. Expert Opin Ther Pat 27 9-15 (2017)
  100. Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase. Frey KM, Bertoletti N, Chan AH, Ippolito JA, Bollini M, Spasov KA, Jorgensen WL, Anderson KS. Front Mol Biosci 9 805187 (2022)
  101. Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs. Boyer PL, Melody K, Smith SJ, Dunn LL, Kline C, Fischer DK, Dwivedi R, Clark P, Hughes SH, Ambrose Z. J Virol 93 (2019)
  102. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. Néant N, Lê MP, Bouazza N, Gattacceca F, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C. Br J Clin Pharmacol 86 2404-2413 (2020)
  103. Who cares for the protons? Czodrowski P. Bioorg Med Chem 20 5453-5460 (2012)
  104. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine. Singh AK, De Wijngaert B, Bijnens M, Uyttersprot K, Nguyen H, Martinez SE, Schols D, Herdewijn P, Pannecouque C, Arnold E, Das K. Proc Natl Acad Sci U S A 119 e2203660119 (2022)
  105. Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties. Prener L, Baszczyňski O, Kaiser MM, Dračínský M, Stepan G, Lee YJ, Brumshtein B, Yu H, Jansa P, Lansdon EB, Janeba Z. J Med Chem 66 1761-1777 (2023)
  106. Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise. Hollander K, Chan AH, Frey KM, Hunker O, Ippolito JA, Spasov KA, Yeh YJ, Jorgensen WL, Ho YC, Anderson KS. Protein Sci 32 e4814 (2023)
  107. Letter Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase. Sasaki T, Gannam ZTK, Kudalkar SN, Frey KM, Lee WG, Spasov KA, Jorgensen WL, Anderson KS. Bioorg Med Chem Lett 29 2182-2188 (2019)
  108. Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT. Minkara MS, Davis PH, Radhakrishnan ML. Proteins 80 573-590 (2012)
  109. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes. DeStefano JJ. Biochemistry 58 2176-2187 (2019)
  110. Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site. Duong VN, Ippolito JA, Chan AH, Lee WG, Spasov KA, Jorgensen WL, Anderson KS. Protein Sci 29 1902-1910 (2020)
  111. Synthesis and molecular docking studies of oxochromenyl xanthenone and indolyl xanthenone derivatives as anti-HIV-1 RT inhibitors. Kasralikar HM, Jadhavar SC, Bhusare SR. Bioorg Med Chem Lett 25 3882-3886 (2015)
  112. The development of an effective synthetic route of rilpivirine. Zhang T, Yang J, Zhou Z, Fu Z, Cherukupalli S, Kang D, Zhan P, Liu X. BMC Chem 15 22 (2021)
  113. "Reverse fleximers": introduction of a series of 5-substituted carbocyclic uridine analogues. Sadler JM, Ojewoye O, Seley-Radtke KL. Nucleic Acids Symp Ser (Oxf) 571-572 (2008)
  114. N-Phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor. Lane T, Makarov V, Nelson JAE, Meeker RB, Sanna G, Riabova O, Kazakova E, Monakhova N, Tsedilin A, Urbina F, Jones T, Suchy A, Ekins S. J Med Chem 66 6193-6217 (2023)
  115. APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants. Dwivedi R, Wang Y, Kline C, Fischer DK, Ambrose Z. Front Virol 2 919825 (2022)
  116. An in-silico approach aimed to clarify the role of Y181C and K103N HIV-1 reverse transcriptase mutations versus Indole Aryl Sulphones. Massarotti A, Coluccia A. J Mol Graph Model 63 49-56 (2016)
  117. Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses. Rattanabunyong S, Choengpanya K, Suwattanasophon C, Kiriwan D, Wolschann P, Lamtha T, Shaikh AR, Rattanasrisomporn J, Choowongkomon K. J Vet Sci 24 e67 (2023)
  118. Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. Jiang X, Huang B, Rumrill S, Pople D, Zalloum WA, Kang D, Zhao F, Ji X, Gao Z, Hu L, Wang Z, Xie M, De Clercq E, Ruiz FX, Arnold E, Pannecouque C, Liu X, Zhan P. Commun Chem 6 83 (2023)
  119. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis. Li SL, Xu P, Zhang L, Sun GX, Lu ZJ. HIV Clin Trials 16 22-29 (2015)
  120. Molecular basis and potential activity of HIV-1 reverse transcriptase toward trimethylamine-based compounds. Padariya M, Kalathiya U, Baginski M. Biotechnol Appl Biochem 64 810-826 (2017)
  121. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase. Barnard JP, Huber KD, Sluis-Cremer N. Antimicrob Agents Chemother 63 e00676-19 (2019)
  122. The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection. Schafer JJ, Ravi S, Rowland EV, Shenoda G, Leon N. P T 36 346-364 (2011)


Related citations provided by authors (4)

  1. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.. Das K, Sarafianos SG, Clark AD, Boyer PL, Hughes SH, Arnold E J Mol Biol 365 77-89 (2007)
  2. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.. Das K, Clark AD, Lewi PJ, Heeres J, De Jonge MR, Koymans LM, Vinkers HM, Daeyaert F, Ludovici DW, Kukla MJ, De Corte B, Kavash RW, Ho CY, Ye H, Lichtenstein MA, Andries K, Pauwels R, De Béthune MP, Boyer PL, Clark P, Hughes SH, Janssen PA, Arnold E J Med Chem 47 2550-60 (2004)
  3. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.. Das K, Ding J, Hsiou Y, Clark AD, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E J Mol Biol 264 1085-100 (1996)
  4. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.. Hsiou Y, Ding J, Das K, Clark AD, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rösner M, Hughes SH, Arnold E J Mol Biol 309 437-45 (2001)

Quick links